18,987 Shares of Sanofi $SNY Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sanofi (NASDAQ:SNY) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 18,987 shares of the company’s stock, valued at approximately $783,000.

Other large investors have also modified their holdings of the company. Profund Advisors LLC boosted its holdings in shares of Sanofi by 12.1% in the 3rd quarter. Profund Advisors LLC now owns 16,097 shares of the company’s stock valued at $664,000 after purchasing an additional 1,733 shares during the last quarter. Vise Technologies Inc. increased its holdings in shares of Sanofi by 11.8% during the 3rd quarter. Vise Technologies Inc. now owns 53,207 shares of the company’s stock worth $2,194,000 after buying an additional 5,623 shares during the last quarter. Intrua Financial LLC increased its holdings in shares of Sanofi by 6.4% during the 3rd quarter. Intrua Financial LLC now owns 5,100 shares of the company’s stock worth $210,000 after buying an additional 309 shares during the last quarter. Raleigh Capital Management Inc. raised its position in shares of Sanofi by 10.2% in the 3rd quarter. Raleigh Capital Management Inc. now owns 69,856 shares of the company’s stock worth $2,880,000 after buying an additional 6,462 shares during the period. Finally, International Assets Investment Management LLC purchased a new position in shares of Sanofi in the 3rd quarter worth $148,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently weighed in on SNY shares. UBS Group reiterated a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research note on Thursday, October 1st. DZ Bank restated a “buy” rating on shares of Sanofi in a report on Friday, July 31st. Berenberg Bank reaffirmed a “buy” rating on shares of Sanofi in a research note on Monday, October 5th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research note on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $49.50.

Sanofi Price Performance

Shares of SNY stock opened at $47.04 on Monday. The firm has a fifty day moving average of $42.30 and a two-hundred day moving average of $44.34. The firm has a market cap of $114.04 billion, a P/E ratio of 23.29, a P/E/G ratio of 1.29 and a beta of 0.31. Sanofi has a 1-year low of $39.07 and a 1-year high of $52.68. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.12 and a quick ratio of 0.27.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.56 by $0.48. Sanofi had a net margin of 8.70% and a return on equity of 15.16%. The business had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.30 billion. During the same quarter in the prior year, the business posted $2.91 EPS. The company’s revenue for the quarter was up 16.2% on a year-over-year basis. As a group, research analysts anticipate that Sanofi will post 5.06 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world.

Sanofi traces its origins to a company established in France in 1973.